{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:08:03Z","timestamp":1764947283157,"version":"3.46.0"},"reference-count":58,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Sustained poor survival rate in pancreatic ductal adenocarcinoma (PDAC) calls for an earlier diagnosis to assure curative treatment. New powerful biomarkers are necessary because the currently used CA19-9 is not sensitive enough to distinguish PDAC, especially from chronic pancreatitis (CP). Expressions of miRNA-21, -30 -192, -196, -200, and -423 were measured in 77 patients with PDAC, 26 patients with CP and 64 non-cancer\/non-CP subjects (39 patients with type 2 diabetes mellitus and 25 control healthy persons). Eleven patients with PDAC had CP at the background. The expressions of all microRNAs were significantly 1.4-3.7 times higher in the PDAC group compared to non-cancer\/non-CP subjects and 2.2-6.1 times higher compared to CP patients. No difference in miRNA expressions was found between diabetic and non-diabetic patients. CA19-9 did not distinguish CP from PDAC patients with the history of CP, whereas all six miRNAs were able to do it. Adding miR-196, -200 and -423 to current marker CA19-9 improved sensitivity by 7 % (to 93 %) and specificity by 8 % (to 89 %). MicroRNA-423 could significantly distinguish PDAC from CP with both sensitivity and specificity 96 %. Panel of six miRNAs could be used as reliable marker in differentiating PDAC from chronic pancreatitis with the most impressive difference in miR-196 and miR-423.<\/jats:p>","DOI":"10.33549\/physiolres.935586","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:03:35Z","timestamp":1764947015000},"page":"837","source":"Crossref","is-referenced-by-count":0,"title":["Serum MicroRNA-196, -200 and -423 Improve Diagnostics and Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis"],"prefix":"10.33549","author":[{"family":"\u0160krha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ho\u0159\u00ednek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hajer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Poto\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fri\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bure\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"And\u011bl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"\u0160krha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSiegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. https:\/\/doi.org\/10.3322\/caac.21442","DOI":"10.3322\/caac.21442"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tLowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno JP, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437. https:\/\/doi.org\/10.1056\/NEJM199305203282001","DOI":"10.1056\/NEJM199305203282001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tJuthani R, Manne A. Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review. Front Oncology 2025:15:1555963. https:\/\/doi.org\/10.3389\/fonc.2025.1555963","DOI":"10.3389\/fonc.2025.1555963"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tWolrab D, Jir\u00e1sko R, C\u00edfkov\u00e1 E, H\u00f6ring M, Mei D, Chocholou\u0161kov\u00e1 M, Peterka O, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun 2022;13:124. https:\/\/doi.org\/10.1038\/s41467-021-27765-9","DOI":"10.1038\/s41467-021-27765-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tHasani F, Masrour M, Khamaki S, Jazi K, Hosseini S, Heidarpour H, Namazee M. Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Cell Molec Med 2025;29:e70337. https:\/\/doi.org\/10.1111\/jcmm.70337","DOI":"10.1111\/jcmm.70337"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tGayral M, Jo S, Hanoun N, Vignolle-Vidoni A, Lulka H, Delpu Y, Meulle A, et al. MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol 2014;20:11199-11209. https:\/\/doi.org\/10.3748\/wjg.v20.i32.11199","DOI":"10.3748\/wjg.v20.i32.11199"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tAl-Temaimi R, Abdulkarim B, Al-Ali A, John B, Mallik MK, Kapila K. Analysis of Candidate miRNAs' Expression in Pancreatic Cancer. Cancer Med 2024;13:e70400. https:\/\/doi.org\/10.1002\/cam4.70400","DOI":"10.1002\/cam4.70400"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tPrzybyszewski O, Mik M, Nowicki M, Kusinski M, Miko\u0142ajczyk-Solinska M, Sliwinska A. Using microRNAs Networks to Understand Pancreatic Cancer-A Literature Review. Biomedicines 2024;12:1713. https:\/\/doi.org\/10.3390\/biomedicines12081713","DOI":"10.3390\/biomedicines12081713"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tKhan IA, Saraya A. Circulating MicroRNAs as Noninvasive Diagnostic and Prognostic Biomarkers in Pancreatic Cancer: A Review. J Gastroint Cancer 2023;54:720-730. https:\/\/doi.org\/10.1007\/s12029-022-00877-1","DOI":"10.1007\/s12029-022-00877-1"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tPowr\u00f3zek T, Otieno MO, Maffeo D, Frullanti E, Martinez-Useros J. Blood circulating miRNAs as pancreatic cancer biomarkers: An evidence from pooled analysis and bioinformatic study. Int J Biol Macromol 2025;308:142469. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142469","DOI":"10.1016\/j.ijbiomac.2025.142469"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tCote GA, Gore AJ, McElyea S, Heathers LE, Xu H, Sherman S, Korc M. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol 2014;109:1942-1952. https:\/\/doi.org\/10.1038\/ajg.2014.331","DOI":"10.1038\/ajg.2014.331"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tMok ETY, Chitty JL, Cox TR. miRNAs in pancreatic cancer progression and metastasis. Clin Exp Metastasis 2024;41:163-186. https:\/\/doi.org\/10.1007\/s10585-023-10256-0","DOI":"10.1007\/s10585-023-10256-0"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tXia T, Chen XY, Zhang YN. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer. Molec Cell Biochem 2021;476:4191-4203. https:\/\/doi.org\/10.1007\/s11010-021-04233-y","DOI":"10.1007\/s11010-021-04233-y"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\t\u0160krha P, Ho\u0159\u00ednek A, Pazourkov\u00e1 E, Hajer J, Fri\u010d P, \u0160krha J, Andel M. Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus. Pancreatology 2016;16:839-843. https:\/\/doi.org\/10.1016\/j.pan.2016.05.005","DOI":"10.1016\/j.pan.2016.05.005"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tSingh N, Khan IA, Rashid S, Rashid S, Roy S, Kaushik K, Kumar A, et al. MicroRNA Signatures for Pancreatic Cancer and Chronic Pancreatitis. Pancreas 2024;53:e260-e267. https:\/\/doi.org\/10.1097\/MPA.0000000000002297","DOI":"10.1097\/MPA.0000000000002297"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tGuo S, Qin H, Liu K, Wang H, Bai S, Liu S, Shao Z, et al. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Clin Transl Med 2021;11:e520. https:\/\/doi.org\/10.1002\/ctm2.520","DOI":"10.1002\/ctm2.520"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tAmerican Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010;33(Suppl 1):S62-S69. https:\/\/doi.org\/10.2337\/dc10-S062","DOI":"10.2337\/dc10-S062"},{"key":"ref17","unstructured":"18.\tBitterlich N, Schneider J. Cut-off-independent Tumour Marker Evaluation Using ROC Approximation. Anticancer Res 2007;27:4305-4310."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tFri\u010d P, \u0160edo A, \u0160krha J, Busek P, Laclav M, Skrha P, Zavoral, M. Early detection of sporadic pancreatic cancer: time for change. Eur J Gastroenterol Hepatol 2017;29:885-891. https:\/\/doi.org\/10.1097\/MEG.0000000000000904","DOI":"10.1097\/MEG.0000000000000904"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\t\u0160krha J, Fri\u010d P, Bu\u0161ek P, \u0160krha P, \u0160edo A. Sporadic pancreatic cancer - glucose homeostasis and pancreatogenic Type 3 diabetes. In: Advances in Pancreatic Cancer. RODRIGO (ed.), InTechOpen, Rijeka, 2018, pp 53-72. https:\/\/doi.org\/10.5772\/intechopen.75740","DOI":"10.5772\/intechopen.75740"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tLopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: Definitions and management. World J Gastroenterol 2014;20:10740-10751. https:\/\/doi.org\/10.3748\/wjg.v20.i31.10740","DOI":"10.3748\/wjg.v20.i31.10740"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tWagner M, Redaelli C, Seiler CA, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-594. https:\/\/doi.org\/10.1002\/bjs.4484","DOI":"10.1002\/bjs.4484"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tBedi MMS, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 2009;28:24-27. https:\/\/doi.org\/10.1007\/s12664-009-0005-4","DOI":"10.1007\/s12664-009-0005-4"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tPoruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. Curr Mol Med 2013;13:340-351. https:\/\/doi.org\/10.2174\/156652413805076876","DOI":"10.2174\/1566524011313030003"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tKawai M, Fukuda A, Otomo R and 38 co-authors. Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. Br J Cancer 2024;131:1158-1168. https:\/\/doi.org\/10.1038\/s41416-024-02794-5","DOI":"10.1038\/s41416-024-02794-5"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tFranklin O, Jonsson P, Billing O, Lundberg E, \u00d6hlund D, Nystr\u00f6m H, Lundin C, Antti H, Sund M. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Ann Surg 2018;267:775-781. https:\/\/doi.org\/10.1097\/SLA.0000000000002124","DOI":"10.1097\/SLA.0000000000002124"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tXue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, et al. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet 2013;206:217-221. https:\/\/doi.org\/10.1016\/j.cancergen.2013.05.020","DOI":"10.1016\/j.cancergen.2013.05.020"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tSlater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Kl\u00f6ppel G, Matth\u00e4i E, et al. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Transl Oncol 2014;7:464-471. https:\/\/doi.org\/10.1016\/j.tranon.2014.05.007","DOI":"10.1016\/j.tranon.2014.05.007"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tHernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 2016;8:18-29. https:\/\/doi.org\/10.4251\/wjgo.v8.i1.18","DOI":"10.4251\/wjgo.v8.i1.18"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tKe RS, Lv LZ, Zhang SY, Zhang FX, Jiang Y. Functional mechanism and clinical implications of MicroRNA-423 in human cancers. Cancer Med 2020;9:9036-9051. https:\/\/doi.org\/10.1002\/cam4.3557","DOI":"10.1002\/cam4.3557"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tZhou Y, Liu Y, Zong Z, Huang H, Liang L, Yang X, Xin M, et al. Rapid and sensitive detection of exosomal microRNAs by terahertz metamaterials. Spectrochim Acta A Mol Biomol Spectrosc 2025;330:125745. https:\/\/doi.org\/10.1016\/j.saa.2025.125745","DOI":"10.1016\/j.saa.2025.125745"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tCao Z, Liu C, Xu JW, You L, Wang C, Lou W, Sun B, et al. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget 2016;7:41575-41583. https:\/\/doi.org\/10.18632\/oncotarget.9491","DOI":"10.18632\/oncotarget.9491"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tLe Large TYS, Meijer LL, Prado MM, Kazemier G, Frampton AE, Giovannetti E. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Expert Rev Mol Diagn 2015;15:1525-1529. https:\/\/doi.org\/10.1586\/14737159.2015.1112273","DOI":"10.1586\/14737159.2015.1112273"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tLiu J, Gao J, Yiqi D, Li Z, Ren Y, Gu J, Wang X, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012;131:683-691. https:\/\/doi.org\/10.1002\/ijc.26422","DOI":"10.1002\/ijc.26422"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tKhan IA, Rashid S, Singh N, Rashid S, Singh V, Gunjan D, Das P, et al. Panel of serum miRNAs as potential 3on invasive biomarkers for pancreatic ductal adenocarcinoma. Sci Rep 2021;11:2824. https:\/\/doi.org\/10.1038\/s41598-021-82266-5","DOI":"10.1038\/s41598-021-82266-5"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tFlammang I, Reese M, Str\u00f6se AJ, Yang Z, Eble JA, Dhayat SA. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers 2020;12:1693. https:\/\/doi.org\/10.3390\/cancers12061693","DOI":"10.3390\/cancers12061693"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tAzadinejad H, Farhadi Rad M, Babaeizad A, Samadi A. MicroRNA profiling in pancreatic cancer and chronic pancreatitis: Novel insights and pathway analysis. Human Gene 2025;44:201410. https:\/\/doi.org\/10.1016\/j.humgen.2025.201410","DOI":"10.1016\/j.humgen.2025.201410"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tLuan X, Wang X, Bian G, Li X, Gao Z, Liu Z, Zhang Z, et al. Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review). Oncol Rep 2025;53:13. https:\/\/doi.org\/10.3892\/or.2024.8846","DOI":"10.3892\/or.2024.8846"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tXu B, Chen Y, Peng M, Zheng JH, Zuo Ch. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma. Int J Cancer 2023;152:110-122. https:\/\/doi.org\/10.1002\/ijc.34195","DOI":"10.1002\/ijc.34195"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tTiwari PK, Shanmugam P, Karn V, Gupta S, Mishra R, Rustagi S, Chouhan M, et al. Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to Therapy. Cancers 2024;16:2179. https:\/\/doi.org\/10.3390\/cancers16122179","DOI":"10.3390\/cancers16122179"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tWlodarczyk B, Durko L, Walczak K, Talar-Wojnarowska R,Malecka-Wojciesko E. Select Endocrine Disorders and Exosomes in Early PDACDiagnosis. Int J Mol Sci 2024;25:12159. https:\/\/doi.org\/10.3390\/ijms252212159","DOI":"10.3390\/ijms252212159"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tOtey CA, Rachlin A, Moza M, Arneman D, Carpen O. The Palladin\/Myotilin\/Myopalladin Family of Actin\u2010Associated Scaffolds. Int Rev Cytol 2005;246:31-58. https:\/\/doi.org\/10.1016\/S0074-7696(05)46002-7","DOI":"10.1016\/S0074-7696(05)46002-7"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tPogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, et al. Palladin Mutation Causes Familial Pancreatic Cancer and Suggests a New Cancer Mechanism. PLoS Med 2006;3:e516. https:\/\/doi.org\/10.1371\/journal.pmed.0030516","DOI":"10.1371\/journal.pmed.0030516"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tSalaria SN, Illei P, Sharma R, Walter KM, Klein AP, Eshleman JR, Maitra A, et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther 2007;6:324-328. https:\/\/doi.org\/10.4161\/cbt.6.3.3904","DOI":"10.4161\/cbt.6.3.3904"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tSato D, Tsuchikawa T, Mitsuhashi T, Hatanaka Y, Marukawa K, Morooka A, Nakamura T, et al. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma. PLoS One 2016;11:e0152523. https:\/\/doi.org\/10.1371\/journal.pone.0152523","DOI":"10.1371\/journal.pone.0152523"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tAlvarez-Teijeiro S, Menendez ST, Angeles Villaronga M, Rodrigo JP, Manterola L, de Villala\u00edn L, de Vicente JC, et al. Dysregulation of Mir-196b in Head and Neck Cancers Leads to Pleiotropic Effects in the Tumor Cells and Surrounding Stromal Fibroblasts. Sci Rep 2017;7:17785. https:\/\/doi.org\/10.1038\/s41598-017-18138-8","DOI":"10.1038\/s41598-017-18138-8"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tXiong M, Wang P, Pan B, Nie J, Wang S, He B. The diagnostic and prognostic values of microRNA-196a in cancer. Biosci Rep 2021;41:BSR20203559. https:\/\/doi.org\/10.1042\/BSR20203559","DOI":"10.1042\/BSR20203559"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tBuck A, Buchholz M, Wagner M, Adler G, Gress T, Ellenrieder V. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer. Mol Cancer Res 2006;4:861-872. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0081","DOI":"10.1158\/1541-7786.MCR-06-0081"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tEllenrieder V, Buck A, Harth A, Jungert K, Buchholz M, Adler G. Urrutia R, Gress TM. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology 2004;127:607-620. https:\/\/doi.org\/10.1053\/j.gastro.2004.05.018","DOI":"10.1053\/j.gastro.2004.05.018"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tSanchez-Cid L, Pons M, Lozano JJ, Rubio N, Guerra-Rebollo M, Soriano A, Paris-Coderch L, et al. MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells. Oncotarget 2017;8:83384-83406. https:\/\/doi.org\/10.18632\/oncotarget.20698","DOI":"10.18632\/oncotarget.20698"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tYu L, Wu D, Gao H, Balic JJ, Tsykin A, Han TS, Liu YD, et al. Clinical utility of a STAT3-regulated microRNA-200 family signature with prognostic potential in early gastric cancer. Clin Cancer Res 2018;24:1459-1472. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2485","DOI":"10.1158\/1078-0432.CCR-17-2485"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tArunkumar G, Rao AKDM, Manikandan M, Rao HPS, Subbiah S, Ilangovan R, Murugan AK, Munirajan AK. Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma. Oncol Lett 2018;15:649-657. https:\/\/doi.org\/10.3892\/ol.2017.7296","DOI":"10.3892\/ol.2017.7296"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tO'Brien SJ, Carter JV, Burton JF, Oxford BG, Schmidt MN, Hallion JC, Galandiuk S. The role of the miR-200 Family in Epithelial-Mesenchymal Transition in Colorectal Cancer: A Systematic Review. Int J Cancer 2018;142:2501-2511. https:\/\/doi.org\/10.1002\/ijc.31282","DOI":"10.1002\/ijc.31282"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tKoutsaki M, Libra M, Spandidos DA, Zaravinos, A. The miR-200 family in ovarian cancer. Oncotarget 2017;8:66629-66640. https:\/\/doi.org\/10.18632\/oncotarget.18343","DOI":"10.18632\/oncotarget.18343"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tSi LB, Tian H, Yue WM, Li L, Li, SH, Gao C, Qi L. Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer. Oncol Lett 2017;14:4325-4330. https:\/\/doi.org\/10.3892\/ol.2017.6667","DOI":"10.3892\/ol.2017.6667"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tLee JS, Ahn YH, Won HS, Sun DS, Kim YH, Ko YH. Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis. Biomed Res Int 2017;2017:1928021. https:\/\/doi.org\/10.1155\/2017\/1928021","DOI":"10.1155\/2017\/1928021"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tBelgardt BF, Ahmed K, Spranger M, Latreille M, Denzler R, Kondratiuk N, von Meyenn F, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med 2015;21:619-627. https:\/\/doi.org\/10.1038\/nm.3862","DOI":"10.1038\/nm.3862"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tLohajov\u00e1 Behulov\u00e1 R, Bugalov\u00e1 A, Bugala J, Struh\u00e1r\u0148ansk\u00e1 E, \u0160afranek M, Jur\u00e1\u0161 I. Circulating Exosomal miRNAs as a Promising Diagnostic Biomarker in Cancer. Physiol Res 2023;72(Suppl 3):S193-S207. https:\/\/doi.org\/10.33549\/physiolres.935153","DOI":"10.33549\/physiolres.935153"}],"container-title":["Physiological Research"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:04:07Z","timestamp":1764947047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_837.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":58,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935586","relation":{},"ISSN":["0862-8408","1802-9973"],"issn-type":[{"value":"0862-8408","type":"print"},{"value":"1802-9973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"847"}}